A new breast cancer drug cut the risk of the disease worsening or death by 59%

For women whose advanced breast cancer had already resisted at least one round of chemotherapy, there is a new reason for hope. Bristol Myers Squibb and SystImmune said on Friday that their experimental treatment, izalontamab brengitecan, reduced the risk of the disease worsening or of death by 59% compared with standard chemotherapy in a late-stage study of hormone-receptor-positive, HER2-negative breast cancer. Patients on the drug lived an average of 8.2 months without their cancer growing, compared with four months on standard chemotherapy. The full results will be presented at the European Society for Medical Oncology congress in Madrid.

SDG 3 · Good health and well-being — Mechanism: tech innovation